Ellevest, Inc. Biomarin Pharmaceutical Inc Transaction History

Ellevest, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$87.74 - $117.27 $6,054 - $8,091	69 Added 18.16%	449 $43,000
Q4 2022 Feb 03, 2023	SELL	$80.93 - $108.63 $19,585 - $26,288	-242 Reduced 38.91%	380 $39,000
Q3 2022 Nov 02, 2022	BUY	$82.16 - $96.94 $37,218 - $43,913	453 Added 268.05%	622 $53,000
Q2 2022 Jul 18, 2022	SELL	$71.48 - $86.85 $8,649 - $10,508	-121 Reduced 41.72%	169 $14,000
Q1 2022 Apr 19, 2022	BUY	$74.28 - $92.69 $6,090 - $7,600	82 Added 39.42%	290 $22,000
Q4 2021 Jan 24, 2022	BUY	$71.72 - $91.47 $2,581 - $3,292	36 Added 20.93%	208 $18,000
Q3 2021 Oct 19, 2021	BUY	$74.77 - $85.47 $4,560 - $5,213	61 Added 54.95%	172 $13,000
Q2 2021 Jul 13, 2021	SELL	$75.51 - $84.79 $6,418 - $7,207	-85 Reduced 43.37%	111 $9,000
Q1 2021 May 03, 2021	SELL	$74.73 - $90.69 $18,981 - $23,035	-254 Reduced 56.44%	196 $15,000
Q4 2020 Feb 04, 2021	BUY	$72.61 - $90.2 $24,179 - $30,036	333 Added 284.62%	450 $39,000
Q3 2020 Oct 26, 2020	BUY	$71.87 - $131.03 $1,365 - $2,489	19 Added 19.39%	117 $9,000
Q2 2020 Jul 06, 2020	BUY	$79.55 - $124.22 $5,091 - $7,950	64 Added 188.24%	98 $12,000
Q1 2020 Apr 13, 2020	BUY	$71.37 - $96.85 $2,426 - $3,292	34 New	34 $3,000
Q3 2019 Oct 08, 2019	SELL	$67.4 - $85.11 $2,561 - $3,234	-38 Closed	0 $0
Q2 2019 Aug 20, 2019	BUY	$80.35 - $93.9 $3,053 - $3,568	38 New	38 $3,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.